DEVIN WENGERT: Open Payments
NPI 1346709557 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 39 payments from 9 companies in 2025. Trend: 2023 $703 · 2024 $1,309 · 2025 $781
Food & beverage: $754Education: $27
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $186 |
| Teva Pharmaceuticals USA, Inc. | 9 | $162 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $91 |
| Janssen Pharmaceuticals, Inc | 3 | $83 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| ABBVIE INC. | 2 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
Products named: ARISTADA, UZEDY, COBENFY, INVEGA SUSTENNA, INGREZZA, ABILIFY MAINTENA, CAPLYTA, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
